Breaking News Instant updates and real-time market news.

AAPL

Apple

$111.57

-0.22 (-0.20%)

, WLL

Whiting Petroleum

$9.68

-0.38 (-3.78%)

07:35
11/29/16
11/29
07:35
11/29/16
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Apple (AAPL), Whiting Petroleum (WLL), AstraZeneca (AZN), ArcelorMittal (MT), Nabors Industries (NBR), Xilinx (XLNX), and Heron Therapeutics (HRTX).

AAPL

Apple

$111.57

-0.22 (-0.20%)

WLL

Whiting Petroleum

$9.68

-0.38 (-3.78%)

AZN

AstraZeneca

$26.73

-0.37 (-1.37%)

MT

ArcelorMittal

$7.56

-0.05 (-0.66%)

NBR

Nabors Industries

$13.50

-0.79 (-5.53%)

XLNX

Xilinx

$53.29

-0.1 (-0.19%)

HRTX

Heron Therapeutics

$15.20

-0.8 (-5.00%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 16

    Feb

AAPL Apple
$111.57

-0.22 (-0.20%)

11/21/16
ADAM
11/21/16
NO CHANGE
Target $140
ADAM
Buy
Apple continues to dominate industry operating profits, says Canaccord
Canaccord analyst T. Michael Walkley said Apple captured a strong share of the premium-tier global smartphone market during Q3 and believes they will continue to extend their leading market share position. He noted Apple will continue to generate strong profit share despite iPhone sales moderating in North America over the past several weeks. Walkley expects steady iPhone 7 sales will help Apple return to growth in Q1 2017 and reiterated his Buy rating and $140 price target on the shares.
11/23/16
CLVD
11/23/16
NO CHANGE
CLVD
Neutral
Apple iPhone 7 supply remains constrained, says Cleveland Research
Cleveland Research said its near-term work remains encouraging on iPhone 7 demand and mix, with checks indicating that supply of iPhone 7 seems to be normalizing in most channels and tightness persists for the 7+. Discussions also suggest growing optimism for the next iPhone refresh, said the firm, which has a Neutral rating on Apple shares.
11/23/16
RSBL
11/23/16
NO CHANGE
RSBL
Apple trimming March quarter component order forecast, says Rosenblatt
Rosenblatt believes Apple has starting trimming its March quarter component order forecast following last week's December quarter production cut. The firm's analyst now expects orders to drop to 40M-43M units from 45M-46M, and believes March quarter's iPhone shipment consensus forecast of 52M-54M may be at risk.
11/29/16
UBSW
11/29/16
NO CHANGE
Target $127
UBSW
Buy
Apple procurement estimates suggest risk to next two quarters, says UBS
UBS analyst Steven Milunovich said Apple's procurement numbers for the December and March quarters have been revised downward, putting consensus estimates for the two quarters at risk. The analyst is leaving his estimates unchanged, but notes his view remains below consensus. He said many investors are looking to 2018, when high retention rates and an aging installed base could drive significant upgrades for the next iteration of the iPhone. Milunovich reiterated his Buy rating and $127 price target on Apple shares.
WLL Whiting Petroleum
$9.68

-0.38 (-3.78%)

10/28/16
RAJA
10/28/16
UPGRADE
Target $16
RAJA
Strong Buy
Whiting Petroleum upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst John Freeman upgraded Whiting Petroleum to Strong Buy and raised its price target to $16 from $14. The analyst said Whiting reported "extremely impressive" Q3 report and now plans to double its Bakken rig count and sees double-digit production growth from current levels in 2017.
10/10/16
RHCO
10/10/16
NO CHANGE
RHCO
Whiting Petroleum named top pick at SunTrust
SunTrust analyst Neal Dingmann named Whiting Petroleum as his top pick. The analyst says that recent developments at the company should enable its production to remain "at least flat," while the company should get a big boost from recent oil price rises.
10/28/16
SPHN
10/28/16
UPGRADE
SPHN
Overweight
Whiting Petroleum upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Will Green upgraded Whiting Petroleum to Overweight from Equal Weight, saying that the "worst may be behind" for the company.
10/05/16
MZHO
10/05/16
INITIATION
Target $9
MZHO
Neutral
Whiting Petroleum initiated with a Neutral at Mizuho
Mizuho analyst Timothy Rezvan initiated Whiting Petroleum with a Neutral and a $9 price target.
AZN AstraZeneca
$26.73

-0.37 (-1.37%)

11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
MT ArcelorMittal
$7.56

-0.05 (-0.66%)

11/25/16
RBCM
11/25/16
UPGRADE
RBCM
Outperform
ArcelorMittal upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Ioannis Masvoulas upgraded ArcelorMittal to Outperform with a price target of EUR 8.20.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Neutral
ArcelorMittal downgraded to Neutral from Buy at Goldman (pre-open)
Pre-open, Goldman analyst Eugene King downgraded ArcelorMittal to Neutral citing year-to-date outperformance.
11/08/16
11/08/16
DOWNGRADE

Neutral
Follow-up: ArcelorMittal downgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill downgraded ArcelorMittal to Neutral from Buy. Analyst Jason Fairclough said Q3 shipments were weaker than the seasonal norm and management guided for comparably low Q4 shipments. He said steel prices are going up but will not fully offset input price pressures and believes Q3 was likely a peak in earnings.
11/08/16
BOFA
11/08/16
DOWNGRADE
BOFA
Neutral
ArcelorMittal downgraded to Neutral from Buy at BofA/Merrill
NBR Nabors Industries
$13.50

-0.79 (-5.53%)

10/28/16
UBSW
10/28/16
NO CHANGE
Target $17
UBSW
Buy
Nabors Industries price target raised to $17 from $12 at UBS
UBS analyst Angie Sedita raised her price target on Nabors Industries to $17 from $12 following the company's analyst day. The analyst believes the overall story remains on track as the company is gaining market share and there is modest pricing traction for high-spec rigs. Sedita also cited the company's new initiatives and its valuation being at a "sharp discount" to its peers, which she feels is unwarranted. Sedita reiterated her Buy rating on Nabors shares.
11/21/16
GSCO
11/21/16
UPGRADE
Target $18
GSCO
Conviction Buy
Nabors Industries upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Waqar Syed added Nabors to the Conviction Buy List and raised its price target to $18 from $16.50 following an increase in 1H 2017 WTI forecast to $55/bbl. The firm said Nabors offers cyclical upside from increased activity, earnings power, and attractive valuation.
09/19/16
SOCO
09/19/16
NO CHANGE
SOCO
Exterran and Nabors added to focus list, Baker Hughes removed at Capital One
10/19/16
GSCO
10/19/16
NO CHANGE
Target $16.5
GSCO
Buy
Goldman says to buy Nabors Industries for earnings and beyond
Goldman analyst Waqar Syed said Nabors will not only benefit from the recent pick-up in US land rig activity, but also offers an above-market growth opportunity from the expansion of ancillary services offered on its rigs. Nabors is targeting $250M in EBITDA from these services in 2-3 years from almost zero today, and should provide further color at its November 10 investor day. Syed expects revenue/margin momentum in Q3 to carry into Q4, given that the current US land rig count is 12% above the Q3 average, and continues to move higher, and recommends buying Nabors for earnings and beyond. The analyst rates Nabors a Buy and increased his price target to $16.50 from $11.50.
XLNX Xilinx
$53.29

-0.1 (-0.19%)

10/18/16
KEYB
10/18/16
NO CHANGE
KEYB
Xilinx can offset Chinese wireless weakness, says KeyBanc
KeyBanc believes that demand for Xilinx's products from Chinese wireless companies is diminishing. However, the firm thinks that the company can offset the negative impact of the slowdown with stabilization in North American wireless capex, ongoing China wireline strength, the joint strike fighter ramp, and the ramp of advanced node products. The firm sees the company as "an attractive M&A target." It keeps a $65 price target and Overweight rating on the shares.
10/12/16
BARD
10/12/16
DOWNGRADE
Target $52
BARD
Neutral
Xilinx downgraded to Neutral at Baird
As reported previously, Baird analyst Tristan Gerra downgraded Xilinx to Neutral from Outperform. Gerra cited valuation, the weakening wireless infrastructure trends, and the likely lack of upside to fiscal 2017 estimates. Gerra maintained his $52 price target on Xilinx shares.
10/12/16
BARD
10/12/16
DOWNGRADE
BARD
Neutral
Xilinx downgraded to Neutral from Outperform at Baird
10/06/16
MZHO
10/06/16
NO CHANGE
MZHO
Buy
Broadcom deal for Xilinx would 'open up' if Qualcomm buys NXP, says Mizuho
Mizuho analyst Vijay Rakesh believes that if Qualcomm (QCOM) acquires NXP Semiconductors (NXPI), as several recent media reports indicate the companies are moving toward, that it "opens up" a deal for Xilinx (XLNX) as an opportunity for Broadcom (AVGO). Rakesh has a Buy rating on Broadcom.
HRTX Heron Therapeutics
$15.20

-0.8 (-5.00%)

10/04/16
BMUR
10/04/16
INITIATION
Target $41
BMUR
Buy
Heron Therapeutics assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Heron Therapeutics with a Buy rating and lowered his price target for the shares to $41 from $55.
11/09/16
COWN
11/09/16
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics price target lowered to $40 from $47 at Cowen
Cowen analyst Boris Peaker lowered his price target on Heron Therapeutics (HRTX) to $40 from $47 following the company's Q3 results. The analyst expects a slow sales ramp for Sustol due to competition, reimbursement dynamics, and Tesaro's (TSRO) early experience with its launch of Varubi. Peaker maintained his Outperform rating on Heron Therapeutics shares.
10/06/16
LEER
10/06/16
NO CHANGE
Target $34
LEER
Outperform
Heron Therapeutics expected to launch Sustol next week, says Leerink
Leerink analyst Jason Gerberry expects Heron Therapeutics to launch Sustol for chemo induced nausea and vomiting on October 11. While the analyst notes that feedback from specialists was mixed, he says they do see a role for Sustol in a subset of more advanced patients who could benefit from a longer-acting drug and/or flexibility of subcutaneous delivery. Nonetheless, Gerberry lowered his Sustol estimates to reflect the final product label and limited window of time to launch in front of generic, but kept an Outperform rating on the shares. He also raised his price target on the stock to $34 from $33 on valuation.
10/26/16
AGIS
10/26/16
INITIATION
Target $41
AGIS
Buy
Heron Therapeutics initiated with a Buy at Aegis
Aegis Jason Wittes analyst initiated Heron Therapeutics with a Buy and a $41 price target.

TODAY'S FREE FLY STORIES

04:40
06/27/17
06/27
04:40
06/27/17
04:40
General news
FX Action: USD-JPY clocked a fresh low of 111.46 »

FX Action: USD-JPY…

03:55
06/27/17
06/27
03:55
06/27/17
03:55
Conference/Events
Federal Reserve Bank President of San Francisco speaks on global growth »

San Francisco Federal…

03:50
06/27/17
06/27
03:50
06/27/17
03:50
General news
Breaking General news story  »

San Francisco Federal…

02:35
06/27/17
06/27
02:35
06/27/17
02:35
General news
FX Update: The dollar majors remained in fairly narrow ranges »

FX Update: The dollar…

NXTM

NxStage Medical

$23.46

0.13 (0.56%)

21:43
06/26/17
06/26
21:43
06/26/17
21:43
Initiation
NxStage Medical initiated at Craig-Hallum »

NxStage Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:40
06/26/17
06/26
21:40
06/26/17
21:40
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

BL

BlackLine

$37.80

-0.26 (-0.68%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
BlackLine initiated at SunTrust »

BlackLine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTI

Ultimate Software

$221.91

-0.25 (-0.11%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Ultimate Software initiated at SunTrust »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CRM

Salesforce

$88.11

-0.51 (-0.58%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Salesforce initiated at SunTrust »

Salesforce initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVBG

Everbridge

$24.66

-0.3 (-1.20%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Everbridge initiated at SunTrust »

Everbridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$37.65

-1 (-2.59%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
RingCentral initiated at SunTrust »

RingCentral initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WK

Workiva

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Workiva initiated at SunTrust »

Workiva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
HubSpot initiated at SunTrust »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
HubSpot initiated at SunTrust »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

QTWO

Q2 Holdings

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Q2 Holdings initiated at SunTrust »

Q2 Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

INST

Instructure

$29.55

0.4 (1.37%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Instructure initiated at SunTrust »

Instructure initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MANH

Manhattan Associates

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Manhattan Associates initiated at SunTrust »

Manhattan Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$47.39

-1.65 (-3.36%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Paylocity initiated at SunTrust »

Paylocity initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

SHOP

Shopify

$92.04

-2.44 (-2.58%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Shopify initiated at SunTrust »

Shopify initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$152.30

0.68 (0.45%)

20:10
06/26/17
06/26
20:10
06/26/17
20:10
Downgrade
LabCorp rating change at KeyBanc »

LabCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATXI

Avenue Therapeutics

20:06
06/26/17
06/26
20:06
06/26/17
20:06
Syndicate
Avenue Therapeutics 5.5M share IPO priced at $6.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NXPI

NXP Semiconductors

$109.73

-0.25 (-0.23%)

20:05
06/26/17
06/26
20:05
06/26/17
20:05
Hot Stocks
NXP Semi collaborates with Shanghai Unicom, roam2free on eSIM solution »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

PDCE

PDC Energy

$42.88

-1.84 (-4.11%)

19:21
06/26/17
06/26
19:21
06/26/17
19:21
Hot Stocks
PDC Energy CEO 'disappointed' with Clean Air Act complaint »

Today, the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MRIN

Marin Software

$1.18

0.025 (2.17%)

19:17
06/26/17
06/26
19:17
06/26/17
19:17
Hot Stocks
Marin Software names Brad Kinnish CFO »

Marin Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

19:15
06/26/17
06/26
19:15
06/26/17
19:15
Earnings
General Motors: Previous FY17 EPS view unchanged »

General Motors said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.